B-cell chronic lymphocytic leukemia

Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies.

The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia.

This gene is also associated with translocations in patients with B-cell chronic lymphocytic leukemia.

B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fludarabine is used to treat B-cell chronic lymphocytic leukemia (CLL).

Upregulation of miR-10b has also been found in B-cell chronic lymphocytic leukemia, the most common type of leukemia.

LEF1 is highly overexpressed and associated with disease progression and poor prognosis in B-cell chronic lymphocytic leukemia.

It is expressed in lymphomas, B-cell chronic lymphocytic leukemia, hairy cell leukemia, and acute nonlymphocytic leukemia.

Michael died at age 70 at Sibley Memorial Hospital on December 24, 2009 after being diagnosed with B-cell chronic lymphocytic leukemia for two years.

Alemtuzumab is approved for treatment of B-cell chronic lymphocytic leukemia and is currently in clinical trials for a variety of other conditions including multiple sclerosis.

Similarly, CD47 ligation rapidly induces apoptosis in B-cell chronic lymphocytic leukemia (CLL) cells.

The drug is also being studied for treatment of B-cell malignancies, including multiple myeloma, B-cell chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.

The DLEU1 gene was originally identified as a potential tumour suppressor gene and is often deleted in patients with B-cell chronic lymphocytic leukemia.

First PI3KI 'Orphan Drug' (for B-cell chronic lymphocytic leukemia (CLL).

As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to initial treatments and with prolonged survival.

Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

Alemtuzumab is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

For example, B-cell chronic lymphocytic leukemia and B-cell small lymphocytic lymphoma are simply different manifestations of the same neoplasm, as are lymphoblastic lymphomas and acute lymphocytic leukemias.

Alemtuzumab is used to treat a certain type of leukemia (B-cell chronic lymphocytic leukemia, also known as B-CLL) in patients who have not responded to other cancer chemotherapy drugs (e.g., fludarabine).

In April 2011, after media speculation that he had suffered kidney failure, James confirmed that he was suffering from B-cell chronic lymphocytic leukemia, and had been under treatment for 15 months at Addenbrooke's Hospital.

Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Perkins JG, Flynn JM, Howard RS, et al.: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.

Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.

GlaxoSmithKline: In December 2006, Genmab entered a deal with GlaxoSmithKline to co-develop and commercialize ofatumumab, which is a drug that could be used for treatment in CD20 positive B-cell chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, rheumatoid arthritis and other indications.